Andrew Hall, IMV CEO

'Very re­al' head­winds: With lean­er staff, can­cer vac­cine mak­er search­es for help

Can­cer vac­cine biotech IMV said it will look at “strate­gic al­ter­na­tives fol­low­ing a re­view of its busi­ness” as the Cana­di­an com­pa­ny con­tin­ues clin­i­cal tri­als.

The No­va Sco­tia and Cam­bridge, MA biotech laid off about one-third of its staff last fall to “max­i­mize share­hold­er val­ue.” Now, IMV wants to “re­al­ize its full clin­i­cal po­ten­tial” in sol­id and hema­to­log­ic can­cers and has tapped Stonegate Health­care Part­ners to fig­ure that out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.